28 October 2020
The World Health Organization (WHO) announced in this week’s WHO Weekly Epidemiological Record that Malawi has been validated to have eliminated lymphatic filariasis as a public health problem.
The World Health Organization (WHO) is developing a toolkit to help programs implement MMDP services. The toolkit incorporates relevant resources developed by WHO and partner institutions, and its objectives are as follows:
provide tools and templates for implementation of key activities to strengthen delivery by the health system of the recommended minimum package of care for LF patients
make information and tools accessible to national LF programs and health professionals around the world
identify and resolve gaps in resources
Components focus on the following areas:
Planning, including patient estimation
Capacity Building to Deliver MMDP Services
Documentation of MMDP services
This report summarizes the 7th meeting of the Global Alliance to Eliminate Lymphatic Filariasis (GAELF), Washington DC, November 18-19, 2012. The theme, “A Future Free of Lymphatic Filariasis: Reaching the Vision by Scaling Up, Scaling Down and Reaching Out”, emphasized new strategies and partnerships necessary to reach the 2020 goal of elimination of lymphatic filariasis (LF) as a public-health problem.
GAELFreport (1.32 MB)
Guide on planning, implementing and monitoring activities at national level. This guide provides the best available information on managing morbidity and preventing disability after acute dermatolymphangioadenitis (ADLA; acute attacks), lymphoedema or elephantiasis, and hydrocoele.
Abstract on the first 8 years of The Global Programme to Eliminate Lymphatic Filariasis. Hooper et al, Annals of Tropical Medicine & Parasitology, Volume 103, 2009 – Issue sup1.
This review examines the thinking and the processes behind the development of albendazole, from the first ideas in the mid 1980s to the establishment of the Global Programme to Eliminate Lymphatic Filariasis.
Abstract on progress made in preventing the disability of lymphatic filariasis, the monitoring and evaluation of such disability and its control, and the integration of disability prevention with mass drug administrations and efforts to control other disabling diseases.
Abstract addressing the central role that filariasis patients have played in the Tanzania Lymphatic Filariasis Elimination Programme to date, and covering some of the clinical successes achieved between 1999 and 2009.
Abstract on the integration of mass drug administrations against multiple NTDs. Hopkins, Annals of Tropical Medicine & Parasitology, Volume 103, 2009 – Issue sup1.
Article on a symposium held to commemorate the 10th anniversary of the donation of Mectizan® and albendazole for the elimination of lymphatic filariasis.
Abstract on the Mectizan® Donation Program (MDP), which was launched in 1987 by Merck & Co., Inc., Kenilworth, N.J., U.S.A.* Thylefors, Annals of Tropical Medicine and Parasitology, 2008 Sep; 102 Suppl 1:39-44.